ATEZOLIZUMAB MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Atezolizumab Market, By Drug Class (PD-L1 Inhibitors, PD-1 Inhibitors, CTLA-4 Inhibitors, Immunomodulators, and Others), By Indication (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin’s Lymphoma, Head and Neck Cancer, and Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Atezolizumab Market Regional Insights

North America is expected to be the largest market for atezolizumab during the forecast period, accounting for over 33.5% of the market share in 2022. The growth of the market in North America is attributed to rising cancer prevalence, new product launches, high healthcare spending, and favorable reimbursements in the region.
Europe is expected to be the second-largest market for atezolizumab, accounting for over 26.2% of the market share in 2022. The growth of the market in Europe is attributed to the availability of research funding, presence of leading pharma giants, and increasing clinical trials evaluating atezolizumab.
Asia Pacific is expected to be the fastest-growing market for atezolizumab, with a CAGR of over 17.1% during the forecast period. The growth of the market in Asia Pacific is attributed to the rising disposable incomes, healthcare infrastructure modernization, and targeted expansion efforts by leading players in the region.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East